touchLearning Activities
The Food and Drug Administration (FDA) has approved ONAPGO™ (apomorphine hydrochloride) sublingual film for the treatment of “off” episodes in Parkinson’s disease (PD), providing patients with a new, on-demand therapy to rapidly alleviate motor symptoms when standard medications wear off.
Sanofi at ECTRIMS 2024. Join MS experts as they examine disability accumulation through the lens of personalised care, biomarkers, and clinical trial design. Hear their perspectives on the complexities of balancing improved relapse management with the ongoing challenge of disability accumulation.
Sanofi at EAN 2024. Hear from the experts about our evolving understanding of multiple sclerosis pathophysiology and the role of smoldering neuroinflammation, with a closer look at microglia and BTK.
Sanofi at AAN 2023. Explore perspectives on MS disability accumulation in the time of highly effective therapies, the smoldering neuroinflammatory pathway, and CNS biomarkers of the future in this Industry Therapeutic Update.
Sanofi at EAN 2023. Learn about the drivers of multiple sclerosis disability accumulation, the unique role of smoldering neuroinflammation, and the role of “big data” in central nervous system biomarkers of the future.
As we move through 2025, touchNEUROLOGY remains committed to sharing the latest developments in Parkinson’s disease (PD). Our society partners at Parkinson’s Europe have outlined three key hopes for the year ahead—each representing a crucial step toward better support, understanding and treatment for the Parkinson’s community.
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is gearing up for its tenth annual Forum, set to take place from February 27 to March 1, 2025, at the Palm Beach County Convention Center and Hilton West Palm Beach in Florida. This year’s theme, “Making Connections,” will emphasize vital links within the brain, between the brain and body, and across the multiple sclerosis (MS) research and clinical communities.
Living with multiple sclerosis (MS) can present numerous challenges, and for individuals in rural communities, those challenges can be even more pronounced. In rural areas, access to MS specialists can be limited, and often rural hospitals and clinics are the primary locations where residents seek diagnosis and care for MS.
Rotterdam (ka). ‘Towards a better headache treatment for everyone’ - The ambitious motto of achieving better headache treatment for everyone was at the centre of the 18th European Headache Congress in Rotterdam. The top-class conference is regarded as an international platform for scientific exchange on the subject of headaches. Confidently chaired by Prof Antoinette Maassen van den Brink, Rotterdam and Prof Jan Versijpt, Brussels, the EHC 2024 Congress was a complete success with around 2,200 participants.
Novartis has announced that its gene therapy, onasemnogene abeparvovec (OAV101 IT), has shown positive results in a late-stage trial for children aged 2 to 18 with spinal muscular atrophy (SMA)
The phase 3b SMART study has shown that 83% of paediatric patients with spinal muscular atrophy (SMA) weighing between 8.5 and 21 kg achieved significant motor improvements following treatment with intravenous onasemnogene abeparvovec in a recent article published in Neurology.
As 2024 draws to a close, we’re celebrating a fantastic year of content.
A new study has revealed that early treatment with ocrelizumab significantly reduces disease activity and long-term progression in patients with early-stage relapsing-remitting multiple sclerosis (RRMS).
touchNEUROLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
